Summary:
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Criteria:- Male or female patients between the ages of 18 and 65 years, inclusive;
- Meets criteria of depression
- Currently having an inadequate response to an anti-depressant treatment
Qualified Participants May Receive:
Compensation for time and travel if they qualify to participate.